Guangqin Li

Guangqin Li


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
CLChenxi Liu
Chenxi Liu
XYXun Yang
Xun Yang
MLMingsu Liu
Mingsu Liu
JWJinping Wang
Jinping Wang
GLGuangqin Li
Guangqin Li

6 October 2023 in Medicine
Verified
Journal Article
Open access
CLChenxi Mm Liu
Chenxi Mm Liu
XYXun Yang
Xun Yang
MLMingsu Liu
Mingsu Liu
JWJinping Wang
Jinping Wang
GLGuangqin Li
Guangqin Li
Background: The use of tirofiban as an adjunct to endovascular therapy (EVT) for acute ischemic stroke has been controversial. We aimed to assess the differences in safety and efficacy of EVT adjuvant to tirofiban in patients with anterior circulation stroke (ACS) and posterior circulation stroke (PCS). Methods: We systematically searched Pubmed, Embase, Cochrane Library, and Web of Science. Cohort studies and randomized controlled trials that compared treatment with tirofiban combined with EVT and EVT alone were included in our meta-analysis. The safety outcomes were symptomatic intracranial hemorrhage, and 3-month mortality. The efficacy outcomes were good functional outcome, excellent functional outcome, and successful recanalization (mTICI ≥ 2b). We performed subgroup analyses of anterior and posterior circulation strokes. Results: We included 15 studies with 4608 patients. For safety outcomes, tirofiban significantly reduced 3-month mortality in the ACS subgroup (odd ratio [OR] = 0.80, 95% confidence interval [CI] = 0.65–0.98, P = .03) without increasing the rate of symptomatic intracranial hemorrhage (OR = 1.12, 95% CI = 0.88–1.44, P = .35). In the PCS subgroup, tirofiban significantly reduced 3-month mortality (OR = 0.63, 95% CI = 0.50–0.80, P = .0001) and symptomatic intracranial hemorrhage (OR = 0.60, 95% CI = 0.37–0.95, P = .03). For efficacy outcomes, in the ACS subgroup, tirofiban significantly improved good functional outcome (OR = 1.24, 95% CI = 1.06–1.45, P = .008) but did not improve recanalization (OR = 1.17, 95% CI = 0.93–1.47, P = .17) and excellent functional outcome (OR = 1.19, 95% CI = 0.97–1.46, P = .10). In the PCS subgroup, tirofiban significantly improved recanalization rate (OR = 1.94, 95% CI = 1.43–2.65, P < .0001) and did not improve good functional outcome (OR = 1.03, 95% CI = 0.81–1.30, P = .81) and excellent functional outcome (OR = 0.84, 95% CI = 0.58–1.20, P = .34). Conclusion: In acute ischemic stroke patients undergoing EVT, tirofiban improves good functional outcomes in ACS patients and increases recanalization rates in PCS patients on the 1 hand, reduces mortality, and does not increase the risk of symptomatic intracranial hemorrhage on the other. Tirofiban is safe and effective in both anterior circulation stroke and posterior circulation stroke patients undergoing EVT. More large multicentre randomized controlled studies are needed in the future.

3 March 2024 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
CLChenxi Liu
Chenxi Liu
MLMingsu Liu
Mingsu Liu
XYXun Yang
Xun Yang
TLTingting Luo
Tingting Luo
JWJinping Wang
Jinping Wang
GLGuangqin Li
Guangqin Li

30 September 2023 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
CLChenxi Liu
Chenxi Liu
MLMingsu Liu
Mingsu Liu
XYXun Yang
Xun Yang
JWJinping Wang
Jinping Wang
GLGuangqin Li
Guangqin Li

1 August 2021 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
YLYong Liu
Yong Liu
GLGuangqin Li
Guangqin Li